Clinical trial
Neoadjuvant Endocrinotherapy of Breast Cancer (Mamma Carcinoma) With Exemestane
NCT00291798 · Austrian Breast & Colorectal Cancer Study Group, Other · Completed
Key facts
| NCT number | NCT00291798 |
|---|---|
| Title | Neoadjuvant Endocrinotherapy of Breast Cancer (Mamma Carcinoma) With Exemestane |
| Official title | Neoadjuvant Endocrinotherapy of Mamma Carcinoma With Exemestane |
| Lead sponsor | Austrian Breast & Colorectal Cancer Study Group, Other |
| Collaborators | Pharmacia Austria GmbH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Procedure |
| Interventions | rate of remission |
| Enrollment | 98 |
| Start date | Sep 1, 2000 |
| Completion | Mar 1, 2009 |
| First posted | Feb 15, 2006 |
| Last update posted | Sep 19, 2006 |
| Countries | Austria |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: